Malaria | Novartis

Media Release
Nov 23, 2022
Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria
Media Release
Jun 23, 2022
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
Story
Apr 19, 2022
Staying one step ahead of the malaria parasite
Story
Apr 07, 2022
Tackling the health toll of climate change
Media Release
Sep 29, 2021
Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria
Media Release
May 18, 2021
Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
Media Release
Mar 03, 2020
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa
Story
Jul 31, 2014
New drugs could offer hope for malaria patients
Story
Apr 09, 2018
Meet Martin Grobusch, malaria fighter
Story
Feb 17, 2014
Text messages in Africa help to fight malaria
Story
Nov 25, 2013
Telemedicine: Taking health care to the world's far corners
Story
Mar 23, 2018
Malaria is still disrupting lives, despite progress